Abstract
Both primary pulmonary hypertension (PPH) and secondary pulmonary hypertension (SPH) have been shown to respond to vasodilator therapy.1-3 In selected patients identified by pulmonary vascular reactivity to an oral calcium-channel blocker challenge, treatment of PPH with high-dose calcium-channel blockers has been demonstrated to prolong survival and lead to regression of right ventricular hypertrophy.4 Subsequently, drugs more selective for the pulmonary vasculature, including prostacyclin, adenosine, and inhaled nitric oxide (INO) have been used to identify patients with a reactive pulmonary vascular bed,5,6 the presence of which has been shown to be of prognostic significance.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
